
Vali oma silt
näidatakse otse viaalilAromasin (Exemestane)
PCT & AI
- Saadetakse Saksamaalt
Tellimus
- DHL koos jälgimisega
- Diskreetne pakend
4.6 5-st Trustpilotis73 arvustust
Otsitud ka nimega: Exemestan
Lühidalt
Aromasin (Exemestane) arvudes
Põhinäitajad meie leksikonist. Lohista punkti mööda kõverat, et näha, kui palju jääb pärast ühte annust arvutuslikult alles.
Täielik leksikoni artikkelHow long does it stay in the body?
Share left after one dose, calculated with a half-life of ~24 hours
Simplified model without an absorption phase, half-life from the TPD lexicon.
Half-life
about24hours
prescribing information, postmenopausal women; 8.9 hours in young men
- Class
- Aromatase inhibitorsteroidal, irreversible
- Use
- Oralevery other day to daily
- Sizes
- 10 to 25 mg2 sizes in the shop
What studies show
All 3 sources in the lexicon- Coombes et al., NEJM, 2004
Absorption, half-life (8.9 hours) and dose finding in young men (opens in a new tab)
Mauras et al., Journal of Clinical Endocrinology and Metabolism, 2003- FDA / DailyMed Label
Arvustused
Mida kliendid ütlevad
Ainult päris tellimused, milles oli Aromasin (Exemestane).
Kõik arvustusedAromasin (Exemestane) jaoks pole veel laborianalüüsi. Hääleta selle pooltLase ise testida, meie maksame pooleKõik laborianalüüsid
Teadmised
Kõik teemal Aromasin (Exemestane)
Üksikasjalik teave tuleb peagi.
Is exemestane approved?
Yes. In the USA it has been marketed as a prescription drug for breast cancer since 21 October 1999, ChEMBL lists phase 4 as the highest phase. It is not approved for men, there is only one short trial in men.
What does the trial in men show?
12 young healthy men took two doses in random order for 10 days each. Estradiol fell by 38 and 32 percent, testosterone rose by 60 and 56 percent. So the higher dose brought no advantage. Blood lipids and IGF-1 stayed unchanged, the strongest reduction was 62 percent 12 hours after intake.
How long does exemestane act?
In young men the peak level came 1 hour after intake and the half-life was 8.9 hours. Estradiol was lowered most after 12 hours and was still clearly lower than at baseline after 24 hours.
What do the breast cancer trials show?
In the Intergroup Exemestane Study 4,742 women switched to exemestane after 2 to 3 years of tamoxifen or stayed on tamoxifen. With exemestane there were 183 instead of 266 first events, the risk fell by 32 percent. In MAP.3 invasive breast cancer fell by 65 percent against placebo in 4,560 women at increased risk.
What happens to bone?
After switching from tamoxifen bone density of the lumbar spine fell by 2.7 percent in the first six months and at the hip by 1.4 percent. In the second year the loss slowed. Fractures occurred in 7 percent against 5 percent on tamoxifen. In the prevention trial against placebo fractures did not differ significantly.
Which side effects have been described?
In the prevention trial 88 percent on exemestane and 85 percent on placebo had any adverse event, quality of life barely changed. Serious toxic effects were rare in the switch trial. In men it was well tolerated over 10 days.
Võrdlused
Kuidas see võrdub
Seotud
Seotud tooted
Clomid (Clomifen)
Ravimid · Kuurijärgne ravi ja aromataasi inhibiitorid Kuurijärgne ravi ja aromataasi inhibiitorid
2 suurust
Tamoxifen (Nolvadex)
Ravimid · Kuurijärgne ravi ja aromataasi inhibiitorid Kuurijärgne ravi ja aromataasi inhibiitorid
2 suurust
Laboris testitud
Arimidex (Anastrozole)
Ravimid · Kuurijärgne ravi ja aromataasi inhibiitorid Kuurijärgne ravi ja aromataasi inhibiitorid
2 suurust
Letrozol (Femara)
Ravimid · Kuurijärgne ravi ja aromataasi inhibiitorid Kuurijärgne ravi ja aromataasi inhibiitorid
2 suurust
Laboris testitud
Aromasin (Exemestane)
